THE ROLE OF THROMBOSIS RISK SCALES LIKE PROGRESSION PREDICTORS OF COVID-19-ASSOCIATED PNEUMONIA.

Objective: The aim: To determine the risk factors for progression by establishing the diagnostic and prognostic role of PPS and ISTH DIC score in patients with COVID-19 required hospitalization.

Patients And Methods: Materials and methods: Main group was 130 patients with COVID-19, divided depending on the severity into 3 subgroups. Patients were examined twice.

A new perspective on bronchial asthma and chronic obstructive pulmonary disease overlap: potential diagnostic criteria.

Objective: The aim: The aim of the research was to analyze the results of observation andexamination of COPD patients in order to identify a group of individualswith potentialasthma overlap.

Patients And Methods: Materials and methods:We have conducted a two-stagedynamic investigation of 43 COPD patients during 3-8 years. The patients were divided into two groups: group 1 counted 30 individuals who presented with at least one episode of reversible bronchial obstruction (RBO) during the observation; group 2 - 13 individuals who presented with nonreversible bronchial obstruction (nonRBO).

Diagnostic role of systemic inflammation, blood coagulation and padua prediction score in lung thrombosis risk estimation in hospitalized patients with community-acquired pneumonia.

Objective: Introduction: Some coagulation and thrombotic disorders during severe CAP could lead to some intravascular disorders and even be the reason of lethal end in hospitalized patients with CAP. But this fact hadn't been established to the end yet. The aim was to study the intravascular changes in patients with severe CAP and to estimate the role of parameters of systemic inflammation (procalcitonin (PCT), C-reactive protein (CRP)), blood coagulation test (fibrinogen, D-dimer, heparin time, prothrombin time) and risk of thrombosis in patients with moderate and severe CAP.

Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.

Background: A primary goal of asthma management is the reduction of exacerbation risk. We assessed the occurrence of oral corticosteroid-requiring exacerbations (OCS exacerbations) with long-term fluticasone/formoterol therapy, and compared it with the occurrence of similar events reported with other inhaled corticosteroid/long acting β2-agonist (ICS/LABA) combinations.

Methods: The occurrence of OCS exacerbations was assessed in two open-label trials of fixed-dose fluticasone/formoterol administered for between 26 to 60 weeks in adults and adolescents with asthma.

Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial.

Objective: To demonstrate the efficacy and safety of fluticasone propionate/formoterol fumarate (flutiform) in a pressurised metered-dose inhaler (pMDI) compared to two formulations of the fluticasone propionate component (Skyepharma fluticasone [SKP FP] or Flovent, GlaxoSmithKline [GSK FP]) in adults and adolescents with moderate-to-severe asthma.

Methods: Patients included in the study were ≥12 years, with symptomatic asthma for ≥1 year, steroid-requiring, had a forced expiratory volume in the first second (FEV1) of 40% to 80% (inclusive) of predicted normal values, and documented reversibility within 12 months of the study. Albuterol/salbuterol was given as rescue medication.

Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.

Background: The inhaled corticosteroid, fluticasone propionate, and the long-acting β(2)-adrenergic agonist, formoterol fumarate, are both highly effective treatments for bronchial asthma. This study (NCT00393952/EudraCT number: 2006-005989-39) compared the efficacy and safety of fluticasone/formoterol combination therapy (flutiform(®); 250/10 μg) administered twice daily (b.i.